In a phase 3 trial dubbed SYNCHRONIZE-1, survodutide—an investigational GLP-1 receptor–glucagon dual agonist—produced significantly greater weight loss than placebo in adults with obesity without diabetes. The trial enrolled 725 participants randomized to once-weekly survodutide dose escalation up to 3.6 mg or 6.0 mg, or placebo, plus lifestyle counseling. At week 76, mean body weight change was -12.2% for 3.6 mg, -13.0% for 6.0 mg, and -5.4% for placebo, with 5% weight loss achieved by 72.6%, 71.9%, and 46.3% respectively. Adverse events were dominated by gastrointestinal symptoms, reported in 80.9% to 89.7% of active-treatment recipients. The study was funded by Boehringer Ingelheim and used treatment-regimen estimands to account for early discontinuation and other protocol factors. The results position survodutide as a new obesity candidate competing in the GLP-1 class, but with a distinct dual-agonist mechanism.